Synthesis of a novel HER2 targeted aza-BODIPY-antibody conjugate : synthesis, photophysical characterisation and in vitro evaluation
We herein report the synthesis and analysis of a novel aza-BODIPY-antibody conjugate, formed by controlled and regioselective bioconjugation methodology. Employing the clinically relevant antibody, which targets HER2 positive cancers, represents an excellent example of an antibody targeting strategy for this class of near-IR emitting fluorophore. The NIR fluorescence and binding properties were validated through in vitro studies using live cell confocal imaging.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2018 |
|---|---|
| Erschienen: |
2018 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:16 |
|---|---|
| Enthalten in: |
Organic & biomolecular chemistry - 16(2018), 7 vom: 14. Feb., Seite 1144-1149 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Cheng, Miffy H Y [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Antibodies |
|---|
| Anmerkungen: |
Date Completed 28.03.2019 Date Revised 28.03.2019 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1039/c7ob02957h |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM280257996 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM280257996 | ||
| 003 | DE-627 | ||
| 005 | 20231225024925.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2018 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1039/c7ob02957h |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0934.xml |
| 035 | |a (DE-627)NLM280257996 | ||
| 035 | |a (NLM)29364306 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Cheng, Miffy H Y |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Synthesis of a novel HER2 targeted aza-BODIPY-antibody conjugate |b synthesis, photophysical characterisation and in vitro evaluation |
| 264 | 1 | |c 2018 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 28.03.2019 | ||
| 500 | |a Date Revised 28.03.2019 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a We herein report the synthesis and analysis of a novel aza-BODIPY-antibody conjugate, formed by controlled and regioselective bioconjugation methodology. Employing the clinically relevant antibody, which targets HER2 positive cancers, represents an excellent example of an antibody targeting strategy for this class of near-IR emitting fluorophore. The NIR fluorescence and binding properties were validated through in vitro studies using live cell confocal imaging | ||
| 650 | 4 | |a Journal Article | |
| 650 | 7 | |a Antibodies |2 NLM | |
| 650 | 7 | |a Boron Compounds |2 NLM | |
| 650 | 7 | |a Immunoconjugates |2 NLM | |
| 650 | 7 | |a Neoplasm Proteins |2 NLM | |
| 650 | 7 | |a azaBDPBA compound |2 NLM | |
| 650 | 7 | |a ERBB2 protein, human |2 NLM | |
| 650 | 7 | |a EC 2.7.10.1 |2 NLM | |
| 650 | 7 | |a Receptor, ErbB-2 |2 NLM | |
| 650 | 7 | |a EC 2.7.10.1 |2 NLM | |
| 700 | 1 | |a Maruani, Antoine |e verfasserin |4 aut | |
| 700 | 1 | |a Savoie, Huguette |e verfasserin |4 aut | |
| 700 | 1 | |a Chudasama, Vijay |e verfasserin |4 aut | |
| 700 | 1 | |a Boyle, Ross W |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Organic & biomolecular chemistry |d 2003 |g 16(2018), 7 vom: 14. Feb., Seite 1144-1149 |w (DE-627)NLM126779694 |x 1477-0539 |7 nnns |
| 773 | 1 | 8 | |g volume:16 |g year:2018 |g number:7 |g day:14 |g month:02 |g pages:1144-1149 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1039/c7ob02957h |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 16 |j 2018 |e 7 |b 14 |c 02 |h 1144-1149 | ||